Nature Reviews Clinical Oncology ( IF 81.1 ) Pub Date : 2017-11-14 , DOI: 10.1038/nrclinonc.2017.175 Alexander Drilon 1, 2 , Zishuo I Hu 3 , Gillianne G Y Lai 4 , Daniel S W Tan 4
Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes, Published online: 14 November 2017; doi:10.1038/nrclinonc.2017.175
NatureArticleSnippet(type=short-summary, markup=The receptor-tyrosine kinase RET has been identified as a potentially actionable driver of oncogenesis. Several multikinase inhibitors with activity against RET have been explored in the clinic, but have only modest efficacy in patients with thyroid cancers, mostly in those with
中文翻译:
针对RET驱动的癌症:来自不断发展的临床前和临床环境的经验教训。
针对RET驱动的癌症:来自不断发展的临床前和临床环境的经验教训
靶向RET驱动的癌症:来自不断发展的临床前和临床环境的经验教训,在线发布:2017年11月14日; doi:10.1038 / nrclinonc.2017.175
NatureArticleSnippet(type = short-summary,markup =受体酪氨酸激酶RET已被鉴定为可能的致癌作用驱动因子。临床上已经探索了几种具有抗RET活性的多激酶抑制剂,但对甲状腺癌患者仅具有中等的疗效,主要是在患有甲状腺癌的患者中。